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ABSTRACT
INTRODUCTION: Langerhans cell histiocytosis is a rare disease (0.4 in 100,000) with a still highly debat-
ed aetiology - either a reactive or a neoplastic process.  It is most commonly divided into single-system and 
multisystem disease. The pulmonary form is part of the former group and occurs mostly in adolescent and 
adult smokers (2nd through 4th decade of life). 
AIM
The aim of this report is to provide more clinical data of one rarely documented disorder. 
MATERIALS AND METHODS: We present a 42-year-old male patient with a respiration-associated pain 
of unknown origin. His physical examination was unremarkable. A CT scan was indicated, revealing mul-
tiple thin-walled cystic lesions and multiple small nodules in the pulmonary parenchyma, predominantly 
in the middle and upper lung segments, which was suggestive of pulmonary Langerhans cell histiocytosis. 
Through a video assisted thoracoscopy, several of the nodules were resected and sent for biopsy.
RESULTS: The patient was discharged on the day after the operation. The biopsy confirmed the diagno-
sis of Langerhans cell histiocytosis. Since systemic corticosteroids were contraindicated in this particular 
case, the patient was counseled to cease smoking. On the follow-up CT a tendency for a reversal of the con-
dition was observed. 
CONCLUSION: The pulmonary form of Langerhans cell histiocytosis is a rare disease, most commonly 
seen in relatively young smokers with non-specific presentation. The biopsy is the only definitive diagnostic 
procedure. The disease may resolve spontaneously or after smoking cessation. In more severe cases cortico-
steroids, chemotherapy or lung transplantation may be considered.
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INTRODUCTION 
Langerhans cell histiocytosis (LCH) is a term 
that describes a wide spectrum of rare disorders all 
of which are associated with the proliferation of im-
mature dendritic cells in the epidermis - the Langer-
hans cells (1). The etiology of this disorder has been 
highly debated in the past. Previous data points out 
that LCH is a reactive process (2) that often brings 
about symptoms associated with inflammatory me-
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other complaints and his physical examination was 
normal and unremarkable: his skin and mucosa were 
pink, his breathing was vesicular, his hearth sounds 
– clear, nothing was palpable in the abdomen and he 
had no peripheral edemas. His lab tests were as fol-
lows: bleeding time – 180 sec. HGB – 156; HCT – 
0.489; PLT – 294; WBC – 11,32; GLU – 6,3; Cre – 56; 
INR – 1.12; PT – 14; FVC1 – 2.48; VC – 3.67; pO2 – 
8.3; pCO2 – 5.3; pH – 7.44. 
A high-resolution computed tomography 
(HRCT) revealed thin-walled cystic lesions, up to 20 
mm in size, in the pulmonary parenchyma bilater-
ally. They had spread diffusely in both lungs, more 
Figure 1
Figure 2
diators, more notably IL-17A, which stimulates den-
dritic fusion (3). On the other hand, newer studies 
have proven the association of the BRAF V600E (1,4) 
and MAP2K1 (5) mutations with LCH, and tip the 
scales in favour of the neoplastic genesis of the dis-
ease. About 40% of the cases of pulmonary Langer-
hans cell histiocytosis (PLCH) are related to a BRAF 
mutation (1). 
The most recent classification outlines a single-
system disease (SS-LCH) and a multisystem disease 
(MS-LCH) on account of the organs involved (6). SS-
LCH includes lesions confined to a single bone or a 
group of bones, the skin, the lungs, the posterior pi-
tuitary, etc (6). In MS-LCH more than one organ is 
involved (6). The hematopoietic system, liver and 
spleen are currently considered high-risk organs (6). 
This article will focus on PLCH.
MATERIALS AND METHODS
We are presenting a 42-year-old male who was 
admitted into the Clinic of Pulmonology and Phthi-
siatry at St. Marina University Hospital for the de-
terioration of respiration-associated pain. He had no 
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profusely in the middle and upper segments. Mul-
tiple subsolid nodules (up to 4 mm) were visualised 
predominantly in the upper pulmonary segments. 
A few (7-8) pretracheal lymph nodes with size up to 
18/8 cm and intact structure were observed. The im-
aging of the lung was highly suspect of Langerhans 
cell hystiocytosis.
On the next day a video-assisted thoracosco-
py (VATS) was performed in order to obtain biopsy 
material. During the procedure, fibrous plaques and 
multiple nodules were observed beneath the pleura 
in all three lobes of the right lung. A couple of the 
nodules were resected from the 2nd and 3rd segment. 
A thoracic drain was placed upon closure.
The histological materials showed pulmonary 
parenchyma with interstitial fibrosis, hemosidero-
sis, inflammation and multiple CD1a-positive large 
Langerhans cells. S100 protein was not expressed in 
these materials.
RESULTS
After the operation, the patient was medicat-
ed with bromhexin, metronidazole, metamizole and 
dexketoprofen and was subsequently discharged af-
ter two days. He was not indicated for systemic ste-
roids, which are frequently prescribed (6), as he was 
also diagnosed with a gastric ulcer. However, the pa-
tient was encouraged to cease smoking as many cases 
of PLCH tend to have complete resolution after such 
actions (6).
During the follow-up, after one month, the pa-
tient confirmed smoking withdrawal. His CT images 
showed that the process in his lungs had a tendency 
for reversal, but still no complete resolution.
DISCUSSION
PLCH occurs most commonly in young smok-
ers, with peak incidence during the 2nd through 
4th decade of life (7). In a Japanese study, the inci-
dence was calculated to be between 0.27 and 0.07 per 
100,000 for men and women, respectively (8). 
The pathogenesis of PLCH is still largely un-
clear in its mechanisms. It is very likely that tobac-
co smoking has a major role, since the majority of the 
patients have a history of smoking or exposure to cig-
arette smoke (9). Very few smokers, however, develop 
PLCH, despite the fact that all are exposed to the ir-
ritant and all of them have an increased macrophage 
numbers in their lungs (10). This hints that perhaps 
there are also endogenous factors involved. One such 
theory suggests that the migratory potential of the 
Langerhans cells is impaired and hence they persist 
in the tracheobronchial tree, where they can form in-
flammatory lesions .
The clinical presentation of PLCH can be very 
scarce. The patients can have cough or dyspnoea, 
which can normally be attributed to smoking. An 
abrupt chest pain can be more alarming and should 
indicate a search for a pneumothorax or rib involve-
ment (11). Spontaneous pneumothorax can occur in 
15-20% of the patients at any time of the treatment 
(7) and also tends to be recurrent (11). Constitutional 
syndromes may be seen in 10–20% of the patients (7). 
Very often the patients are asymptomatic (11).
Usually cysts and nodules seen on CT are con-
sidered the only diagnostically relevant image (6). 
The alteration areas are usually located in the upper 
and middle segments, sparing the lower ones, with 
centrilobular distribution and size <1cm in the ear-
ly stages of the disease (12). The only definitive meth-
od of diagnosis is a biopsy stained with CD1a or S100 
protein, with the latter being non-specific (11). The 
differential diagnosis usually includes sarcoidosis, 
silicosis, tuberculosis, metastatic disease, cavitated 
Pneumocystis jirovecii lesion, etc. (12).
The treatment in the ideal case involves smok-
ing withdrawal as many patients’ conditions resolve 
after that or at least improve drastically (6). Low-
dose systemic corticosteroids are most common-
ly applied in patients with more progressive symp-
toms (6). Other, more potent immunosuppressive 
drugs can be used, like cladribine (2-cDa), which is 
reported to downregulate the histiocyte proliferation 
and has direct toxicity for monocytes and lympho-
cytes (7,14). However, the prophylaxis for lung infec-
tions in this case should be much greater and also 
cover Pneumocystis jirovecii and the herpes viruses 
(7). Trimethoprim/sulfamethoxazole and valaciclo-
vir have been used in some of the cases (7,15). Vin-
blastine, despite being a first-line choice in chemo-
therapy in MS-LCH in children (6), has little effect 
in adult patients with PLCH (7,16). Lung transplan-
tation has also been used in patients with end-stage 
PLCH (17). Despite the recurrence of the disease, in 
about 20% of the patients, it has a good posttrans-
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plant survival rate (57.2% at 5 years) (17) and should 
be considered in patients who start to develop pul-
monary hypertension (17).
CONCLUSION
PLCH is a rare disease, which often has an un-
remarkable clinical presentation. However, with dil-
igent use of the current imaging modalities, and a 
mandatory biopsy of every nodular lesion, the diag-
nosis can be confirmed quickly. Very often the sole 
treatment is to remove the main pathogenic factor, 
i.e. the tobacco smoke, from the environment of the 
patient. This very often leads to a complete resolu-
tion. More aggressive treatments can be used under 
careful control in patients with systemic disease. 
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